Malaria vaccine tests successful

A Swiss biotechnology company has said that it has successfully tested a malaria vaccine which could be marketed as early as 2014, according to a statement from directors.

Mymetics, who acquired the trial vaccine from Swiss research and development company Pevion Biotech, said it had carried out clinical trials on humans in Britain and Switzerland.

Studies on Tanzanian children and teenagers in areas where malaria is prevalent are also underway, Mymetics said.

It added that further experiments on substances which create antibodies that resist the infection were also in the pipeline. It could take up to three years to complete clinical trials, which would set a timetable of roughly six years for the vaccination to obtain full approval, Mymetics chief executive Christain Rochet added.

Possible HIV/Aids vaccine also being tested
"There is a pressing need for a vaccine against malaria," he said. "Up to 500 million people a year are infected, with a mortality rate of approximately two million each year."

Malaria is a deadly parasitic infection passed on from infected mosquitoes to humans, and strikes mainly in tropical and sub-tropical environments.

Mymetics said it is also testing a possible vaccine against the HIV-Aids virus and tests will start later this year on 33 women in Belgium.

It said it would not market the vaccines, but would seek to sell them to a major pharmaceutical group. - (Sapa, May 2008)

Read more:
Malaria vaccine shows promise
UN plans to curb malaria deaths

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes
27% - 9950 votes
No
73% - 26296 votes
Vote